Apogee Therapeutics, Inc. (APGE) - Stock Analysis
Last updated: Jun 21, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong clinical catalyst after Phase 2 APEX Part B met all primary and secondary endpoints on 2026-05-27, supported by major funding, AbbVie deal speculation, and about 61% 21-day momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Position ⢠Ongoing Losses ⢠Dilution-Driven Funding APGE has exceptional liquidity and minimal debt, but with no revenue, persistent losses, and cash burn driven by financing rather than operations, it remains a high-risk, richly valued turnaround bet.
Price Behavior
Key Price Behavior Insights: ⢠Strong rebound buying ⢠Near-term resistance ⢠Key support zone Support Level: $82-$87 Resistance Level: $90-$91 Over the last month, APGE has climbed about 11% in a constructive uptrend, showing strong rebound buying but now facing near-term resistance around $90-$91 with support at $86-$87 and stronger support at $82-$83.
Sentiment & News
Key News Insights: ⢠Phase 3 ready ⢠Funding secured ⢠M&A optionality Apogee's strong Phase 2 zumilokibart results, up to $1.3B in Blackstone financing, and reported AbbVie takeover interest have materially improved the near-term outlook and late-stage execution path.
AI Summary
APGE has shifted from a speculative biotech to a more de-risked clinical asset with enough cash and strategic financing to fund Phase 3, but the investment now hinges on confirming its Phase 2 atopic dermatitis signal in late-stage trials because the stock already prices in meaningful upside while still carrying single-program and no-revenue risk.
Description
Apogee Therapeutics is a biotechnology firm developing biologic therapies for atopic dermatitis, COPD and related inflammatory and immunological conditions. Its lead programs are subcutaneously administered, extended half-life monoclonal antibodies advancing in AD and COPD, with additional earlier-stage antibody programs for AD. The company was founded in 2022 and is headquartered in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 22 | Jun 29 | APGE | Apogee Therapeutics, Inc. | Strong clinical catalyst after Phase 2 APEX Part B met all primary and secondary endpoints on 2026-05-27, supported by major funding, AbbVie deal speculation, and about 61% 21-day momentum. | Active | +0.0% |
| Mar 26 | Apr 2 | APGE | Apogee Therapeutics, Inc. | Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16âweek topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52âweek APEX Part A durability data released 2026â03â23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21âday ROC ~+10.8% and price ~9% above its 21âday SMA, the setup is a classic eventâdriven biotech hot idea. | Closed | +7.5% |